Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, to launch Caris Target Now Select, an advanced, evidence-based molecular profiling service for patients with cancers of the breast, colon, and ovary, non-small cell lung cancer (NSCLC), and melanoma.
The new service offering will augment the Caris Target Now service line and also include an enhanced version of the company’s original comprehensive molecular profiling service for all solid tumours.
The new service incorporates numerous, updated, evidence-based technologies to determine the genomic information unique to a patient’s tumour. Key features of this new service will include ‘on-compendium only’ drug associations, faster turnaround time, the capability to derive meaningful results from smaller tissue samples, up to 30 reported biomarkers per patient (depending on tumor type), and biomarker-specific clinical trial matching.
“Caris Target Now Select represents the latest step forward in biomarker analysis, as it points the way toward appropriate, tumour-specific therapy for more patients, even in the earlier stages of cancer,” said Tom Spalding, Oncology senior vice president and Group Head at Caris Life Sciences. “Since the clinical utility of any single technology for biomarker analysis is limited, the Caris Target Now suite of services incorporates all relevant technologies to decode the entire cancer biological process of a patient’s tumor — from DNA mutation and gene rearrangements, to RNA and protein expression. This thorough approach provides detailed information to aid physicians in navigating the increasing number of therapeutic options both within and beyond the standard of care.”
Caris Target Now Select will utilize the strongest clinical evidence to highlight associations with appropriate therapies for the five target tumor types, as identified in the National Comprehensive Cancer Network Drug & Biologics Compendium. Its availability will complement the newly enhanced version of Caris’ original molecular profiling service (now renamed Caris Target Now Comprehensive), which provides both on- and off-Compendium therapeutic associations for all solid tumours, across a wide range of evidence.